Loading
Life sciences · Journal article
Frontiers in Surgery · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Fibrous dysplasia (FD) is a rare benign fibro-osseous bone lesion, while diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Their clinical and imaging manifestations overlap substantially, which complicates diagnosis, particularly when DLBCL manifests as extranodal bone lesions without peripheral lymphadenopathy. The coexistence of jaw FD and DLBCL is extremely rare, and relevant clinical experience is insufficient. Case description This report presents a 46-year-old female with a 40-year history of jaw FD who presented with progressive right mandibular swelling and pain for 2 months. Laboratory tests showed elevated alkaline phosphatase. Imaging revealed right mandibular bone destruction, and pathological examination confirmed non-germinal center B-cell-like (non-GCB) DLBCL limited to the skeletal system, with double-expressor lymphoma features. The patient was staged as IIIA with an intermediate-low International Prognostic Index (IPI) and intermediate-high National Comprehensive Cancer Network International Prognostic Index(NCCN-IPI) risk. She received 8 cycles of polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin hydrochloride and prednisone (Pola-R-CHP) chemotherapy, achieving partial relief of symptoms and reduced mandibular mass, but residual lesions remained. Subsequently, second-line dexamethasone, high-dose cytarabine and cisplatin (DHAP) salvage therapy was initiated due to persistent disease activity. Conclusions The coexistence of FD and DLBCL is easily misdiagnosed as FD progression. For FD patients with new-onset bone destruction and mass formation, timely pathological biopsy is essential to confirm malignancy. Accurate imaging, pathological evaluation, and risk stratification guide treatment selection. First-line chemoimmunotherapy may achieve partial remission in refractory cases, and second-line intensive salvage regimens are needed for persistent disease. This case provides a reference for the diagnosis and treatment of similar rare complex cases.